Pipecolinic acidCAS# 535-75-1 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 535-75-1 | SDF | Download SDF |
| PubChem ID | 849 | Appearance | Powder |
| Formula | C6H11NO2 | M.Wt | 129.07 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | piperidine-2-carboxylic acid | ||
| SMILES | C1CCNC(C1)C(=O)O | ||
| Standard InChIKey | HXEACLLIILLPRG-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C6H11NO2/c8-6(9)5-3-1-2-4-7-5/h5,7H,1-4H2,(H,8,9) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Pipecolic acid is a metabolite of lysine, it is a salivary metabolite biomarker. |
| In vitro | Investigation and identification of potential biomarkers in human saliva for the early diagnosis of oral squamous cell carcinoma.[Pubmed: 24144867 ]Clin Chim Acta. 2014 Jan 1;427:79-85.Oral cancer is 1 of the 6 most common human cancers, with an annual incidence of >300,000 cases worldwide. This study aimed to investigate potential biomarkers in human saliva to facilitate the early diagnosis of oral squamous cell carcinoma (OSCC).
|
Pipecolinic acid Dilution Calculator
Pipecolinic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 7.7477 mL | 38.7387 mL | 77.4773 mL | 154.9547 mL | 193.6933 mL |
| 5 mM | 1.5495 mL | 7.7477 mL | 15.4955 mL | 30.9909 mL | 38.7387 mL |
| 10 mM | 0.7748 mL | 3.8739 mL | 7.7477 mL | 15.4955 mL | 19.3693 mL |
| 50 mM | 0.155 mL | 0.7748 mL | 1.5495 mL | 3.0991 mL | 3.8739 mL |
| 100 mM | 0.0775 mL | 0.3874 mL | 0.7748 mL | 1.5495 mL | 1.9369 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Apohyoscine
Catalog No.:BCN1870
CAS No.:535-26-2
- 4-Methoxycinnamyl alcohol
Catalog No.:BCN7515
CAS No.:53484-50-7
- Creticoside C
Catalog No.:BCN5707
CAS No.:53452-34-9
- 16-Kaurene-2,6,15-triol
Catalog No.:BCN5706
CAS No.:53452-32-7
- Vaccarin
Catalog No.:BCN2277
CAS No.:53452-16-7
- 2-Aminonicotinic acid
Catalog No.:BCC8552
CAS No.:5345-47-1
- D-Leu-ol
Catalog No.:BCC2583
CAS No.:53448-09-2
- 2-Aminodiphenylamine
Catalog No.:BCC8548
CAS No.:534-85-0
- Erteberel (LY500307)
Catalog No.:BCC4491
CAS No.:533884-09-2
- Isovitexin 2'-O-arabinoside
Catalog No.:BCN7826
CAS No.:53382-71-1
- 1,3,5-Trihydroxy-4-prenylxanthone
Catalog No.:BCN5705
CAS No.:53377-61-0
- trans,trans-Bis(4-fluorobenzal)acetone
Catalog No.:BCC9180
CAS No.:53369-00-9
- Trigonelline
Catalog No.:BCN2371
CAS No.:535-83-1
- Marein
Catalog No.:BCN6477
CAS No.:535-96-6
- PIT 1
Catalog No.:BCC7873
CAS No.:53501-41-0
- 4,9,9'-Trihydroxy-3,3'-dimethoxy-8,4'-oxyneolignan
Catalog No.:BCN1425
CAS No.:53505-68-3
- 7-Amino-4-(Trifluoromethyl)Coumarin
Catalog No.:BCC9208
CAS No.:53518-15-3
- Durantoside II
Catalog No.:BCN4622
CAS No.:53526-66-2
- Durantoside I
Catalog No.:BCN4621
CAS No.:53526-67-3
- Luteolin-3-O-beta-D-glucuronide
Catalog No.:BCN3826
CAS No.:53527-42-7
- Apigenin 7-O-methylglucuronide
Catalog No.:BCN5708
CAS No.:53538-13-9
- Benzoyl-L-histidine
Catalog No.:BCC8866
CAS No.:5354-94-9
- Diaveridine
Catalog No.:BCC8936
CAS No.:5355-16-8
- (-)-Bicuculline methochloride
Catalog No.:BCN3763
CAS No.:53552-05-9
Investigation and identification of potential biomarkers in human saliva for the early diagnosis of oral squamous cell carcinoma.[Pubmed:24144867]
Clin Chim Acta. 2014 Jan 1;427:79-85.
BACKGROUND: Oral cancer is 1 of the 6 most common human cancers, with an annual incidence of >300,000 cases worldwide. This study aimed to investigate potential biomarkers in human saliva to facilitate the early diagnosis of oral squamous cell carcinoma (OSCC). METHODS: Unstimulated whole saliva obtained from OSCC patients (n=30) and apparently healthy individuals (n=30) were assayed with ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) in hydrophilic interaction chromatography mode. The data were analyzed using a nonparametric Mann-Whitney U test, logistic regression, and the receiver operating characteristic (ROC) to evaluate the predictive power of each of 4 biomarkers, or combinations of biomarkers, for OSCC screening. RESULTS: Four potential salivary biomarkers demonstrated significant differences (P<0.05) in concentrations between patients at stages I-II and the healthy individuals. The area under the curve (AUC) values in control vs OSCC I-II mode based on choline, betaine, Pipecolinic acid, and l-carnitine were 0.926, 0.759, 0.994, and 0.708, respectively. Four salivary biomarkers in combination yielded satisfactory accuracy (0.997), sensitivity (100%), and specificity (96.7%) in distinguishing OSCC I-II from control. CONCLUSIONS: Salivary metabolite biomarkers for the early diagnosis of OSCC were verified in this study. The proposed approach is expected to be applied as a potential technique of preclinical screening of OSCC.
